Ziccum AB (publ) (ZICC.ST)
SEK 0.35
(-9.07%)
SEK 0.35
(-9.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -23.28 Million SEK | -1679.57% |
| 2022 | -1.35 Million SEK | 87.81% |
| 2021 | -11.12 Million SEK | 17.09% |
| 2020 | -13.41 Million SEK | -91.11% |
| 2019 | -7.02 Million SEK | -87.15% |
| 2018 | -3.75 Million SEK | -2064.04% |
| 2017 | -173.33 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -6.21 Million SEK | 21.59% |
| 2024 Q1 | -766 Thousand SEK | 90.79% |
| 2024 Q2 | -7.92 Million SEK | -934.73% |
| 2023 FY | -24.13 Million SEK | -1679.57% |
| 2023 Q3 | -4.53 Million SEK | 20.36% |
| 2023 Q2 | -5.69 Million SEK | -1800.9% |
| 2023 Q1 | 335 Thousand SEK | 199.11% |
| 2023 Q4 | -8.31 Million SEK | -83.3% |
| 2022 Q1 | -2.74 Million SEK | 25.87% |
| 2022 FY | -1.35 Million SEK | 87.81% |
| 2022 Q4 | -338 Thousand SEK | 90.89% |
| 2022 Q3 | -3.71 Million SEK | 21.12% |
| 2022 Q2 | -4.7 Million SEK | -71.63% |
| 2021 Q4 | -3.69 Million SEK | -33.3% |
| 2021 Q3 | -2.77 Million SEK | -10.03% |
| 2021 Q2 | -2.52 Million SEK | -18.46% |
| 2021 Q1 | -2.12 Million SEK | -17.82% |
| 2021 FY | -11.12 Million SEK | 17.09% |
| 2020 FY | -13.41 Million SEK | -91.11% |
| 2020 Q3 | -4.38 Million SEK | -13.45% |
| 2020 Q4 | -1.8 Million SEK | 58.81% |
| 2020 Q2 | -3.86 Million SEK | -15.3% |
| 2020 Q1 | -3.35 Million SEK | -23.76% |
| 2019 Q4 | -2.71 Million SEK | -177.1% |
| 2019 Q3 | -978 Thousand SEK | 47.14% |
| 2019 Q2 | -1.85 Million SEK | -25.51% |
| 2019 Q1 | -1.47 Million SEK | 0.27% |
| 2019 FY | -7.02 Million SEK | -87.15% |
| 2018 Q1 | -102 Thousand SEK | -78.95% |
| 2018 Q2 | -449 Thousand SEK | -340.2% |
| 2018 FY | -3.75 Million SEK | -2064.04% |
| 2018 Q4 | -1.47 Million SEK | 4.4% |
| 2018 Q3 | -1.54 Million SEK | -244.32% |
| 2017 Q2 | -8000.00 SEK | 0.0% |
| 2017 FY | -173.33 Thousand SEK | 0.0% |
| 2017 Q4 | -57 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 85.508% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 106.724% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 155.725% |
| Mendus AB (publ) | 28.48 Million SEK | 181.743% |
| Genovis AB (publ.) | 54 Million SEK | 143.121% |
| Intervacc AB (publ) | -13.79 Million SEK | -68.813% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 1172.593% |
| Active Biotech AB (publ) | -1.67 Million SEK | -1290.209% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 333.725% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 186.82% |
| Aptahem AB (publ) | 2.63 Million SEK | 985.181% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -580.678% |
| Kancera AB (publ) | -1.96 Million SEK | -1085.038% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 30341.558% |
| Fluicell AB (publ) | 1.73 Million SEK | 1439.816% |
| Saniona AB (publ) | 11.78 Million SEK | 297.657% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -355.071% |
| Biovica International AB (publ) | 6.87 Million SEK | 438.607% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -0.013% |
| AcouSort AB (publ) | 8.38 Million SEK | 377.578% |
| Xintela AB (publ) | 78 Thousand SEK | 29953.846% |
| Abliva AB (publ) | -35.66 Million SEK | 34.705% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 84.148% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 929.569% |
| OncoZenge AB (publ) | 3000.00 SEK | 776300.0% |
| Amniotics AB (publ) | -1.93 Million SEK | -1106.528% |
| 2cureX AB (publ) | -37.48 Million SEK | 37.882% |
| CombiGene AB (publ) | -21.29 Million SEK | -9.372% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -5404.965% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 102.061% |
| Camurus AB (publ) | 1.58 Billion SEK | 101.473% |
| Corline Biomedical AB | 28.38 Million SEK | 182.051% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 81.027% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 32.338% |
| I-Tech AB | 27.56 Million SEK | 184.474% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 132.82% |
| Cyxone AB (publ) | 2.61 Million SEK | 991.842% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 784.279% |
| Biosergen AB | -456 Thousand SEK | -5006.579% |
| Cantargia AB (publ) | -3.45 Million SEK | -574.761% |
| NextCell Pharma AB | -43.74 Million SEK | 46.773% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -153.274% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 307.572% |
| Nanologica AB (publ) | -76 Thousand SEK | -30539.474% |
| SynAct Pharma AB | -778 Thousand SEK | -2893.059% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -11965.285% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -80.204% |
| Lipum AB (publ) | 53 Thousand SEK | 44035.849% |
| BioInvent International AB (publ) | 71.46 Million SEK | 132.586% |
| Alzinova AB (publ) | 19.87 Million SEK | 217.168% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 164.151% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 1691.639% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -155140.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 1504.463% |
| Simris Alg AB (publ) | 2 Million SEK | 1260.239% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -550.447% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 165.802% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -2119.828% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 843.249% |